If you’d like to explore how ketamine therapy or Spravato (esketamine) treatment could help depression and anxiety, we invite you to book a complimentary consultation below. We look forward to speaking with you.
Does Cigna cover ketamine therapy or treatment?
Latest medical review on: July 9th, 2025. Medically reviewed by Chief Medical Officer Dr. Ben Yudkoff.
Cigna covers the FDA-approved version of ketamine called Spravato (esketamine), a highly effective solution for treating depression. However, Cigna does not cover intravenous (IV) or intramuscular (IM) ketamine treatment for conditions associated with depression, anxiety, or other mood disorders.
Key Takeaways: Does Cigna cover ketamine for mental health?
• Cigna covers Spravato (esketamine) for depression, which is a nasal spray formulation of ketamine boasting similar efficacy
• This is because Spravato (esketamine) has full FDA approval for the treatment of treatment-resistant depression through Johnson & Johnson
• Your coverage may vary based on your specific plan. Get in touch with Lumin Health to explore your options. We handle all prior authorization on your behalf to make this process as seamless as possible.
• This is because Spravato (esketamine) has full FDA approval for the treatment of treatment-resistant depression through Johnson & Johnson
• Your coverage may vary based on your specific plan. Get in touch with Lumin Health to explore your options. We handle all prior authorization on your behalf to make this process as seamless as possible.
Does Cigna cover Spravato therapy or esketamine treatment?
Yes. Cigna covers Spravato (esketamine) treatment for people suffering from Treatment Resistant Depression (TRD). Costs are typically a co-pay, and allow for ongoing treatment. Schedule a consultation with us to see if you qualify.
Does Cigna cover ketamine infusions or ketamine injections for mental health?
Cigna tyically does not cover intramuscular ketamine injections. When it comes to ketamine, Cigna will likely Spravato (esketamine) treatment and Cigna will typically not cover ketamine infusions or ketamine injections. We would be grateful to review your coverage with you; simply get in touch with our team.
Ketamine Infusions vs. Spravato (Esketamine): What's the Difference for Cigna Patients?
Spravato is the "s-enantiomer" of ketamine and has a different pathway for coverage and prior authorization than traditional ketamine therapy through intravenous or intramuscular administration. Knowing this key difference can be crucial to finding the correct coverage information.
Does Lumin Health accept Cigna for Spravato treatment?
Yes, Lumin Health accepts Cigna insurance for initial psychiatric consults, Spravato (esketamine) therapy, and ongoing care. Esketamine therapy is a great option for those looking for ketamine therapy, and provides very similar benefits for those dealing with mood and mental health issues.
How can I get Spravato (esketamine) covered by Cigna?
The criteria for getting ketamine therapy with Spravato covered by Cigna can vary based on each case, but some commonalities are below.
Individual is 18 years of age or older
Meets Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria
Has had an inadequate response to four antidepressants from at least 2 different antidepressant classes
Individual does not have any FDA labelled contraindications to esketamine nasal spray
Learn more about the specific insurance coverage for esketamine therapy and Spravato with Cigna. For more information about how Lumin Health works with insurance, visit our insurance cost & information page.
Frequently asked questions
What is the cost of ketamine treatment with Cigna?
Is ketamine FDA-approved?
Does Cigna cover ketamine for depression, PTSD, and chronic pain?
How do I get pre-authorization for Spravato (esketamine)?
How do I know if I’m a good candidate for ketamine therapy, and how can I start treatment?
Article Reviewed by Dr. Benjamin Yudkoff, MD, MA
Dr. Yudkoff is a board-certified psychiatrist who provides the most up-to-date psychiatric care to people managing illnesses that have not satisfactorily resolved with treatment as usual, and in a way which honors principles of autonomy, self-direction, and holistic approaches. He has lectured on spirituality and ketamine therapy, is an Instructor in Psychiatry at Harvard Medical School, and has taught a humanism course to residents of the Harvard Brigham and Women’s Hospital Residency Training Program. Dr. Yudkoff has served as the Medical Director of the Brigham and Women’s Faulkner Hospital and the Medical Director of the Interventional Psychiatric Service (electroconvulsive therapy, ketamine, and esketamine). Dr. Yudkoff has published scientific articles on ketamine and psychopharmacology, and has won several teaching awards from Harvard Medical School students and Brigham and Women’s Psychiatric Residents.
Locations and Hours
